https://pittplusme.org/study/1704
HCC 19-120: Advanced Prostate Cancer Study
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Have you been diagnosed with metastatic castration-resistant prostate cancer? If so, you may be eligible for a research study to help find out if combining two investigational drugs, called niraparib and JNJ-63723283, is effective as a treatment for metastatic prostate cancer. Reimbursement provided for travel and meals for each visit.
IRB: 6137-LJAppleman
- A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
AGE:
18 and up
SEX ASSIGNED AT BIRTH:
Male
VISITS:
Multiple visits
LOCATION:
UPMC Hillman Cancer Center sites in Monroeville, Upper St. Clair, Passavant, Shadyside, & Arnold Palmer Mt. View (Greensburg), St. Margaret
COMPENSATION:
Reimbursed between $54 to $78 per visit
SHARE STUDY
MEET THE RESEARCHER
Leonard Appleman
Leonard J. Appleman, MD, PhD, is an Associate Professor of Medicine in the Division of Hematology/Oncology. A graduate of New York University School of Medicine, Dr. Appleman’s research interests include the development of novel therapeutics for kidney cancer, prostate cancer, and other malignancies.